Abbott Launches SimpleScreen™ CRC Blood Test, Joining Cologuard Plus® in Its Colorectal Cancer Screening Portfolio

Abbott Labs launches blood test to screen for colorectal cancer

Abbott Laboratories’ cancer diagnostic wing, formerly Madison-based Exact Sciences, is launching a blood test to screen for colorectal cancer.

Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio

/PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC)...

Abbott launches Freenome’s colorectal cancer screening test

Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.

Abbott rolls out SimpleScreen CRC blood test across US

Abbott has commercially rolled out SimpleScreen CRC in the US, introducing the FDA-approved blood test for colorectal cancer screening.

Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening

Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.

Abbott unveils SimpleScreen CRC blood test, joining Cologuard Plus in its colorectal cancer screening portfolio

SimpleScreen CRC expands screening options for adults age 45 and older, providing another way to help reach people who otherwise may remain unscreened.